Cocrystal Pharma, Inc. (COCP)
COCPNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.00
-0.1450 (-12.66%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $21.29m
- P/E
- –
- EPS, last 4 quarters
- $-0.7600
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.7600 to $2.03
- Average volume
- 42.6k
- Previous close
- $1.15
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $6.00, +500.0% from here
Earnings
next estimate $-0.1700Next report Nov 13, 2026
Sep 2025
+13.6%
Dec 2025
+5.6%
Mar 2026
-13.3%
Jun 2026
-35.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | $225.0k | $105.0k |
| Gross profit | – | – | $225.0k | $105.0k |
| Operating income | -$2.09m | -$2.48m | -$2.36m | -$3.18m |
| Net income | -$2.05m | -$2.43m | -$2.30m | -$3.16m |
News
8 latest- Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Norovirus Study RTTNews · Sep 9, 2026
- Cocrystal Pharma Names James Sapirstein CEO, Stock Up In Pre-market RTTNews · Jun 3, 2026
- Cocrystal Pharma (COCP) Price Target Increased by 33.33% to 8.16Fintel · Apr 14, 2026
- Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus RTTNews · Apr 2, 2026
- Cocrystal Pharma (COCP) Price Target Increased by 14.29% to 8.16Fintel · Oct 29, 2025
- Cocrystal Pharma Narrows Loss in Q2The Motley Fool · Aug 14, 2025
- Cocrystal Pharma Announces Promising Results for CDI-988 as Treatment for Rising Norovirus GII.17 StrainQuiver Quantitative · Apr 24, 2025
- COCRYSTAL PHARMA Earnings Preview: Recent $COCP Insider Trading, Hedge Fund Activity, and MoreQuiver Quantitative · Apr 5, 2025
The company
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create viable antiviral drugs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- cocrystalpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.